Compare BioNano Genomics Inc (BNGO) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Prudential PLC — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Prudential PLC trades at $29.15 (market cap $35.11B). The key difference: Prudential PLC is far larger — about 2659.8× BioNano Genomics Inc's market cap, and Prudential PLC pays a 1.86% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | PUK | |
|---|---|---|
Market Cap | $13.20M | $35.11B |
Sector | Health | Financials |
52-Week High | $4.92 | $33.61 |
52-Week Low | $1.09 | $24.65 |
Enterprise Value | $15.81M | $36.55B |
Dividend Yield | — | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Prudential (PUK) trades at $28.40, up 0.96% with bullish technical signals from moving averages. The stock shows strong fundamentals with a P/E of 9.25, net income margin of 14.52%, and ROE of 21.15%. Recent earnings beat expectations in Q2 and Q4 2025, while analyst consensus leans bullish with 50% buy ratings. Positive news includes JP Morgan's catalyst watch ahead of August results and strategic expansion in India.
Outlook remains positive with improving cash flow trends and debt reduction. Key opportunities include Asia growth exposure and strong profitability metrics. Risks include China regulatory uncertainty and Japan sales suspension impacts. The stock presents value with attractive valuation multiples and analyst support for upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
